Short Interest in Xenetic Biosciences Inc (NASDAQ:XBIO) Decreases By 43.2%

Xenetic Biosciences Inc (NASDAQ:XBIO) saw a significant decrease in short interest in November. As of November 15th, there was short interest totalling 8,400 shares, a decrease of 43.2% from the October 31st total of 14,800 shares. Based on an average daily volume of 20,500 shares, the short-interest ratio is presently 0.4 days. Approximately 0.7% of the shares of the stock are sold short.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “neutral” rating on shares of Xenetic Biosciences in a report on Friday, November 22nd.

Xenetic Biosciences Stock Performance

Shares of NASDAQ XBIO opened at $4.26 on Friday. The firm has a market cap of $6.56 million, a P/E ratio of -1.60 and a beta of 2.25. Xenetic Biosciences has a 1 year low of $2.78 and a 1 year high of $5.20. The firm’s 50 day moving average price is $3.94 and its 200 day moving average price is $3.93.

Xenetic Biosciences (NASDAQ:XBIO) last released its earnings results on Tuesday, November 12th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.14). Xenetic Biosciences had a negative net margin of 161.63% and a negative return on equity of 49.51%. The business had revenue of $0.61 million during the quarter, compared to analyst estimates of $0.75 million. As a group, equities analysts predict that Xenetic Biosciences will post -1.01 EPS for the current year.

Xenetic Biosciences Company Profile

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.